The biotech industry faces a mix of longstanding and novel political challenges amid President Donald Trump’s second term.

The pending deal was rumored overnight after a report from the Financial Times, spurring analysts to speculate that if true, ...

Solar stocks slid in off-hours trading after Senate Republicans kept in a full phase-out of solar and wind energy tax credits in [President Trump's budget bill]( ...

Ticker: Second patient death reported with gene therapy for muscular dystrophy; Salmonella poisoning linked to pistachio ...

Shares of Sarepta Therapeutics have plunged again after the drugmaker reported a second death in connection with its gene ...

How the U.S. FDA might respond became a serious question for Wall Street as Sarepta Therapeutics Inc. made known a second death due to acute liver failure with gene therapy Elevidys (delandistrogene ...

François-Henri Pinault is stepping back as CEO of Kering, hoping Luca de Meo can pull Gucci and Saint Laurent's parent company out of a slump. Attorneys General Sign $7.4 Billion Purdue Pharma Opioid ...

Sarepta Therapeutics Inc. plummeted after reporting a second patient died of acute liver failure while being treated with its gene therapy for a rare muscle disorder.The death of the 15-year-old boy ...

To date, over 900 Duchenne patients have been treated with delandistrogene moxeparvovec. "The signal for ALF is exceptionally rare and has only emerged in the non-ambulatory patients," Sarepta's CEO ...

Sarepta Therapeutics said a second patient had died after receiving its $3.2 million gene therapy to treat Duchenne muscular ...

Shares of Sarepta Therapeutics closed down as much as 42% to hit a nine-year low of $18.30 on Monday after a second death of ...

Another gene therapy death of a Duchenne patient has some parents and doctors criticizing the FDA's actions, even as other ...